Hostname: page-component-74656f9884-npj9w Total loading time: 0 Render date: 2026-11-07T12:43:13.922Z Has data issue: false hasContentIssue false

An overview on Leishmania (Mundinia) enriettii: biology, immunopathology, LRV and extracellular vesicles during the host–parasite interaction

Published online by Cambridge University Press:  10 December 2017

Larissa F. Paranaiba
Affiliation:
Departamento de Parasitologia, Universidade Federal de Minas Gerais – UFMG, Av. Antônio Carlos, 6627 – Pampulha, 31270-901, Belo Horizonte, Minas Gerais, Brazil
Lucélia J. Pinheiro
Affiliation:
Departamento de Patologia Geral, Universidade Federal de Minas Gerais – UFMG, Av Antônio Carlos, 6627 – Pampulha, 31270-901, Belo Horizonte, Minas Gerais, Brazil
Diego H. Macedo
Affiliation:
Centro de Pesquisas René Rachou/Fundação Oswaldo Cruz – CpqRR/FIOCRUZ, Av. Augusto de Lima, 1715 – Barro Preto, 30.190-009, Belo Horizonte, Minas Gerais, Brazil
Armando Menezes-Neto
Affiliation:
Centro de Pesquisas René Rachou/Fundação Oswaldo Cruz – CpqRR/FIOCRUZ, Av. Augusto de Lima, 1715 – Barro Preto, 30.190-009, Belo Horizonte, Minas Gerais, Brazil
Ana C. Torrecilhas
Affiliation:
Departamento de Farmácia, Universidade Federal de São Paulo – UNIFESP, Av. São Nicolau, 210, 09913-030, Diadema, São Paulo, Brazil
Wagner L. Tafuri
Affiliation:
Departamento de Patologia Geral, Universidade Federal de Minas Gerais – UFMG, Av Antônio Carlos, 6627 – Pampulha, 31270-901, Belo Horizonte, Minas Gerais, Brazil
Rodrigo P. Soares*
Affiliation:
Centro de Pesquisas René Rachou/Fundação Oswaldo Cruz – CpqRR/FIOCRUZ, Av. Augusto de Lima, 1715 – Barro Preto, 30.190-009, Belo Horizonte, Minas Gerais, Brazil
*
Author for correspondence: Rodrigo P. Soares, E-mail: rsoares@cpqrr.fiocruz.br

Abstract

One of the Leishmania species known to be non-infective to humans is Leishmania (Mundinia) enriettii whose vertebrate host is the guinea pig Cavia porcellus. It is a good model for cutaneous leishmaniasis, chemotherapeutic and molecular studies. In the last years, an increased interest has emerged concerning the L. (Mundinia) subgenus after the finding of Leishmania (M.) macropodum in Australia and with the description of other new/putative species such as L. (M.) martiniquensis and ‘L. (M.) siamensis’. This review focused on histopathology, glycoconjugates and innate immunity. The presence of Leishmania RNA virus and shedding of extracellular vesicles by the parasite were also evaluated.

Information

Type
Special Issue Review
Copyright
Copyright © Cambridge University Press 2017 
Figure 0

Fig. 1. Distributions and hosts of Leishmania species from the L. (Mundinia) subgenus. Legend: CL, cutaneous leishmaniasis; VL, visceral leishmaniasis.

Figure 1

Fig. 2. Schematic diagram of lipophosphoglycan repeat units from Leishmania enriettii strains. The repeat units are 6-Gal(β1,4)Man(α1)-PO4.

Figure 2

Table 1. Innate immune components involved in LPG and GIPLs activation by different Leishmania species

Figure 3

Fig. 3. LRV1/LRV2 absence in two Leishmania enriettii strains (L88 and Cobaia). Legend: M, molecular marker; C1+, LVR1-positive control (Leishmania guyanensis reference strain M4147); C−, LRV1-negative control (Leishmania braziliensis reference strain M2903); C2+, LVR2-positive control (Leishmania major reference strain ASKH); lane 1, strain L88; lane 2, strain Cobaia; NC, negative controls (capsid and β-tubulin).

Figure 4

Fig. 4. Extracellular vesicles release by Leishmania enriettii strains (L88 and Cobaia strain). Scanning electron microscopy (SEM) of parasite membrane shedding after incubation in culture medium (a–d, bars: 3–10 µm). (a, b) L. enriettii L88 strain, (c, d) L. enriettii Cobaia strain. Magnification: (a) 26 468; (b) 50 000; (c) 15 276 and (d) 50 000.

Figure 5

Fig. 5. Nanoparticle tracking analysis (NTA) and dot-blot from Leishmania enriettii strains (L88 and Cobaia). (a) NTA analysis from EVs released by L88 and (b) Cobaia strains (c); size exclusion chromatoghraphy (SEC) of EVs from Cobaia strain, and (d) gp63 detection of EV-containing fractions probed with mAb anti-gp63 (1:500).